Analysis of VEGF-A/VEGFR1/VEGFR2 gene expression in patients with myelodysplastic syndrome

作者：Kalitin N N^*; Dudina G A; Semochkin S V; Karamysheva A F

来源：Terapevticheskii Arkhiv, 2017, 89(7): 39-44.

DOI：10.17116/terarkh201789739-44

• myelodysplastic syndromes
• VEGF-A, VEGFR1, and VEGFR2 gene expression

Aim. To assess the significance of gene expression of the vascular endothelial growth factor-A (VEGF-A) and its interacting receptors VEGFRI and VEGFR2 as potential diagnostic and prognostic molecular markers in patients with myelodysplastic syndrome (MDS).
Materials and methods. A real time polymerase chain reaction (RT-PCR) assay was used to investigate the gene expression of VEGFA, VEGFR1, and VEGFR2 in the mononuclear cell fractions obtained from 24 patients with MDS.
Results. The expression of the 3 genes was identified in all the patients examined. There was the highest expression level of the VEGF-A gene (p<0.0001), whereas the expression of the VEGFR1 gene was higher than that of the VEGFR2 gene (p<0.001). The expression of the VEGF-A gene proved to be higher in patients at a higher risk of acute leukemia and positively correlated with the expression levels of the VEGFR1 gene (p<0.05) rather than that of the VEGFR2 gene. At the same time, patients with higher VEGFR1 gene expression had significantly lower overall survival rates (r=-0.5; p<0.05). Patients with intermediate-2 or high-risk acute leukemia showed an increase in the average expression levels of VEGF-A and VEGFRI and a reduction in VEGFR2 expression.
Conclusion. This investigation revealed correlations between the number of blast cells in patients with MDS and the expression levels of the VEGF-A gene and between the overall survival of patients with MDS and the expression levels of the VEGFRI gene rather than those of the VEGF-A and VEGFR2 genes.

• 出版日期2017